secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001213900-24-013668
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics issues $440K convertible note to 3i, LP; amends Series A conversion price to $0.405
--------------------------------------------------------------------------------

- Second closing of $440K principal senior convertible note purchased for $400K (10% original issue discount), due February 2025.
- Note carries 8% annual interest, convertible at $0.405 per share; Purchaser limited to 4.99% beneficial ownership cap.
- Limited Waiver Agreement permits second closing before the 30-day waiting period required by the original purchase agreement.
- Conversion price of Series A Preferred Stock amended from $0.4476 to $0.405 via Sixth Certificate of Amendment filed with Delaware.
- Net proceeds to be used for accounts payable and working capital; negative covenants restrict additional indebtedness over $250K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/ea193650-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-013668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer